Logo

ELUT

Elutia Inc.

ELUT

Elutia Inc. • NASDAQ
$0.61 ▼ -8.86% (-0.06)
Market Cap $26.09 M
52w High $5.12
52w Low $0.58
Dividend Yield 0%
P/E -0.61
Volume 169.84K
Outstanding Shares 42.53M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $3.323M ▼ $7.061M ▼ $-3.868M ▲ -116.401% ▲ $-0.009 ▲ $2.162M ▲
Q2-2025 $6.263M ▲ $12.933M ▲ $-9.61M ▼ -153.441% ▼ $-0.23 ▼ $-8.192M ▼
Q1-2025 $6.03M ▲ $10.379M ▼ $-3.933M ▲ -65.224% ▲ $-0.1 ▲ $-1.972M ▲
Q4-2024 $5.468M ▼ $10.756M ▼ $-9.061M ▼ -165.71% ▼ $-0.26 ▲ $-7.126M ▼
Q3-2024 $5.922M $12.971M $1.286M 21.716% $-0.36 $3.285M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $4.721M ▼ $29.407M ▼ $73.325M ▼ $-43.918M ▼
Q2-2025 $8.5M ▼ $33.849M ▼ $75.692M ▼ $-41.843M ▼
Q1-2025 $17.358M ▲ $39.298M ▲ $75.756M ▼ $-36.458M ▲
Q4-2024 $13.239M ▼ $36.127M ▼ $82.387M ▼ $-46.26M ▼
Q3-2024 $25.741M $48.407M $88.645M $-40.238M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $0 ▲ $0 ▲ $0 ▲ $0 ▲ $-3.779M ▲ $0 ▲
Q2-2025 $-9.61M ▼ $-8.228M ▲ $-114K ▲ $-516K ▼ $-8.858M ▼ $-8.342M ▲
Q1-2025 $-3.933M ▲ $-8.881M ▲ $-278K ▼ $13.278M ▲ $4.119M ▲ $-9.159M ▲
Q4-2024 $-9.061M ▼ $-12.257M ▼ $-94K ▲ $-151K ▼ $-12.502M ▼ $-12.351M ▼
Q3-2024 $1.067M $-3.427M $-547K $11.527M $7.553M $-3.974M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Cardiovascular
Cardiovascular
 $0 ▲$0 ▲$0 ▲$0 ▲
Womens Health
Womens Health
 $10.00M ▲$0 ▼$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Elutia’s income statement looks like a classic early‑stage biotech/medtech story: very small revenue, gross profit that is positive but modest, and operating expenses that are much larger than its sales. Losses have been persistent every year, and while there has been some slight improvement recently, the company is still far from break‑even. The business today is driven more by investment in products and market development than by revenue scale, so profitability remains a medium‑ to long‑term possibility rather than a near‑term feature.

Balance Sheet

Balance Sheet The balance sheet shows a lean company that has absorbed years of losses. Total assets are modest, cash has trended down over time, and shareholder equity has moved from positive to negative, meaning accumulated losses now exceed the capital invested. Debt is meaningful compared with the size of the asset base, which heightens financial risk and dependence on outside funding or transactions. Overall, the balance sheet underlines that Elutia is still financially fragile and needs successful execution on its strategy to strengthen its capital position.

Cash Flow

Cash Flow Elutia has consistently used cash in its operations, with outflows that have been fairly steady year after year. Free cash flow is negative and closely tracks operating cash flow, because the business spends very little on long‑term physical assets and is relatively asset‑light. This pattern shows a company that relies on financing activities, partnerships, or asset sales to fund its development rather than internally generated cash. The recent sale of a major product line to a larger industry player (described in the narrative) fits this pattern: it helps relieve funding pressure but doesn’t yet show up in the historical cash flow figures provided.

Competitive Edge

Competitive Edge Elutia occupies a specialized niche at the intersection of biologics and medical devices. Its drug‑eluting biomatrix technology and expertise in regenerative scaffolds give it a differentiated story versus generic biologic meshes or purely synthetic implants. The sale of its cardiac bioenvelope products to a major multinational validated the technology and brand, but also removed an established product line from its portfolio. Today, Elutia’s competitive position rests on SimpliDerm in breast reconstruction and its cardiovascular matrices, where it faces large, well‑funded competitors with broader sales infrastructure. Its advantages are in product design, proprietary processing, and clinical focus; its weaknesses are scale, financial resources, and commercial reach compared with big medtech and biologics players.

Innovation and R&D

Innovation and R&D Innovation is where Elutia stands out. The company has already demonstrated that it can take a novel drug‑eluting biomatrix from concept to FDA clearance and then to a significant strategic sale. Its current R&D focus is on bringing that same core technology into breast reconstruction, a market with meaningful complications that its products aim to reduce. The NXT‑41 platform, with a base matrix followed by a drug‑eluting version, is the central bet: if successful in regulatory review and clinical adoption, it could reshape the company’s revenue mix and growth profile. The cardiovascular portfolio and SimpliDerm also reflect a consistent strategy of using biologic scaffolds designed to behave more like natural tissue. The main risks are typical for this kind of company: regulatory uncertainty, clinical performance versus competitors, and the challenge of turning strong science into sustained commercial traction.

Summary

Overall, Elutia looks like a high‑innovation, high‑risk, early‑stage healthcare company that is still in the build‑out phase. Financially, it has small revenue, ongoing losses, negative equity, and steady cash burn, which make it dependent on external capital and strategic deals. Strategically, it has a clear, focused story built around drug‑eluting biomatrices, with past validation from a major asset sale and a pipeline targeted at a large, clinically important market in breast reconstruction. The investment case around Elutia hinges less on current financial strength and more on whether its focused portfolio, regulatory milestones, and commercialization plans can translate its technology into a sustainable, larger‑scale business over the next several years, amid significant execution and funding uncertainties.

NEWS

November 6, 2025 · 4:05 PM UTC

Elutia Reports Third Quarter 2025 Financial Results; Closes $88 Million Sale of BioEnvelope Business to Boston Scientific Corporation; Funds NXT-41x Development

Read more

October 23, 2025 · 4:05 PM UTC

Elutia to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025

Read more

October 14, 2025 · 4:05 PM UTC

Elutia to Present at the LD Micro Main Event XIX Conference on Tuesday, October 21

Read more

October 10, 2025 · 8:00 AM UTC

Elutia Appoints Accomplished MedTech Veteran Guido J. Neels to Board of Directors

Read more

October 1, 2025 · 8:41 AM UTC

Elutia Announces Closing of BioEnvelope Business Sale to Boston Scientific Corporation for $88 Million

Read more